Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.

[powerpress]

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, discusses the issue of patients or payers objecting to repeat biopsies.

[powerpress]

Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular testing for, and which molecular markers are the highest priority.

[powerpress]

Dr. Geoffrey Oxnard conveys a central theme that the benefits of molecular oncology and optimal application of targeted therapies are dependent on a change in collecting tissue that works to obtain far more tissue than was historically required.

[powerpress]

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing patients with advanced NSCLC who experience acquired resistance, the progression of cancer after a good initial response to a targeted therapy.

[powerpress]

Dr. Geoffrey Oxnard describes the new finding of individuals with an inherited T790M mutation in the EGFR gene, the unclear significance of it, and a study being conducted to learn more about it.

[powerpress]